Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson’s Disease
Condition(s):Parkinson DiseaseLast Updated:February 5, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Parkinson DiseaseLast Updated:February 5, 2021Completed
Condition(s):Parkinson DiseaseLast Updated:February 7, 2020Unknown status
Condition(s):Irritable Mood; Aggression; Traumatic Brain InjuryLast Updated:April 25, 2022Completed
Condition(s):Covid19Last Updated:October 6, 2021Unknown status
Condition(s):Parkinson’s DiseaseLast Updated:November 13, 2019Terminated
Condition(s):Postoperative Cognitive DysfunctionLast Updated:June 20, 2019Unknown status
Condition(s):Glioblastoma MultiformeLast Updated:February 23, 2024Recruiting
Condition(s):Stroke, Ischemic; Stroke HemorrhagicLast Updated:February 21, 2024Recruiting
Condition(s):Parkinson’s Disease; Levodopa Induced Dyskinesia (LID)Last Updated:February 16, 2022Terminated
Condition(s):Spinal CurvaturesLast Updated:January 12, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.